Orchid Chemicals receives FDA approval for Cefoxitin injection

By Angela McDaniels

Seattle, Jan. 27 - Orchid Chemicals & Pharmaceuticals Ltd. said the Food and Drug Administration has approved the company's abbreviated New Drug Application for injectable Cefoxitin, 1 gm/vial and 2 gm/vial.

Cefoxitin is a generic version of Merck's antibiotic Mefoxin.

"We are extremely happy about this product approval. Though Cefoxitin has been off-patent for a while, Orchid is the second generic company to enter this product space and hence we expect a good market share and revenues," managing director K. Raghavendra Rao said in a company news release.

The company will launch the product in the United States exclusively through Apotex Corp. of Weston, Fla.

Orchid is a Chennai, India, pharmaceutical company that develops and manufactures bulk drugs and formulations.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.